Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over extension study of iptacopan in PNH patients from prior Phase 2/3 trials
jRCT2021210059Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of iptacopan. Started Dec 2021; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2021210059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210059.